Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of olorofim versus AmBisome followed by standard of care for invasive aspergillosis
MOH_2022-02-15_010590Phase 3Active, not recruiting
- Sponsor
- F2G
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in invasive aspergillosis (IA) comparing Olorofim arm with AmBisome followed by standard of care arm (2 arms). Primary endpoint: All-cause mortality at Day 42. Started Feb 2022; status: active, not recruiting.
02
Drugs
olorofimamphotericin b
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on MOH_2022-02-15_010590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-02-15_010590.